REG-PanGenomic Health Inc: Board Changes

Pangenomic HealthAnnouncement

14/07/2023 07:15

14 July 2023

 

PanGenomic Health Inc.

(“PanGenomic” or the “Company”)

 

Board Changes

 

Vancouver, British Columbia, Canada, 13 July 2023 – PanGenomic Health Inc.
("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), announces
that independent directors, Peter Green and Jonathan Lutz, tendered their
resignations effective as of 12 July 2023.

 

"We wish to thank Peter and Jonathan for all of their valuable guidance as
PanGenomic matured from a private health tech startup to one of the first
publicly-listed benefit companies in both Canada and the UK last year", said
Robert Nygren, Executive Chair and Co-Founder of PanGenomic Health.

 

The Company will immediately commence the process of identifying and
appointing two new independent directors and will make further announcements
in due course.

 

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalised, evidence-based information about
natural treatments. The Company’s initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

 

The Directors of PanGenomic take responsibility for this announcement.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

 

For more information, please contact:

 

Jerry Lai, Investor Relations    Maryam Marissen, President & CEO

PanGenomic Health Inc.    PanGenomic Health Inc.

778 743 4642      778 743 4642

ir@pangenomic.com     info@pangenomic.com

 

Novum Securities Limited, AQSE corporate Advisor

David Coffman / George Duxberry

Tel: +44 (0)207 399 9400

 

Yellow Jersey PR
Charles Goodwin / Shiv Thambirajah / Soraya Jackson
Investor Relations, UK
Tel: +44 (0)20 3004 9512

 

This news release includes certain statements that may be deemed
“forward-looking statements”, including statements respecting the services
to be provided by PanGenomic Health and the consideration to be paid to
PanGenomic Health. The use of any of the words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”,
“would”, “project”, “should”, “believe” and similar
expressions are intended to identify forward looking statements. Although
PanGenomic Health believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance should not
be placed on the forward-looking statements because PanGenomic Health can give
no assurance that they will prove to be correct. Since forward-looking
statements address future events and conditions, by their very nature they
involve inherent risks and uncertainties. These statements speak only as of
the date of this News Release. Actual results could differ materially from
those currently anticipated due to a number of factors and risks including
various risk factors discussed in PanGenomic Health’s disclosure documents
which can be found under PanGenomic Health’s profile on www.sedar.com.

 

 



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved